Brescia R J, Dubin N, Demopoulos R I
Department of Pathology, New York University School of Medicine, New York.
Int J Gynecol Pathol. 1989;8(2):132-8. doi: 10.1097/00004347-198906000-00006.
Eighty-five patients, 52 with endometrioid carcinoma (EC), nine with mixed endometrioid and clear cell carcinoma (MC), and 24 with clear cell carcinoma (CC), were studied to determine if prognosis was affected by (a) mixed tumor histology, (b) grade of the endometrioid component in ECs, and MCs, (c) presence of benign or malignant squamous differentiation in ECs, (d) solid versus tubular histology in CCs, (e) endometriosis in the same ovary as the tumor or elsewhere in the pelvis, (f) tumor stage, (g) patient age, or (h) presence of a coexisting carcinoma of the endometrium. The 5 year survivals for the ECs, MCs, and CCs were 52%, 22%, and 69%, respectively, for all stages. The 5 year survivals for Stage I ECs and CCs were 82% and 93%, respectively. None of these differences were statistically significant. Higher stages of disease for all three tumor types and higher grades of the endometrioid component of the ECs and the MCs were associated with significantly decreased survival. Patients with CCs had a significantly increased incidence of pelvic endometriosis (67%) versus patients with ECs (17%) or MCs (22%) (p less than 0.001). Survival was not significantly affected by benign or malignant squamous differentiation in ECs, tubular differentiation in CCs, patient age, the presence of endometriosis, or a coexisting carcinoma of the endometrium.
对85例患者进行了研究，其中52例为子宫内膜样癌（EC），9例为子宫内膜样癌与透明细胞癌混合癌（MC），24例为透明细胞癌（CC），以确定预后是否受以下因素影响：（a）混合肿瘤组织学类型；（b）EC和MC中子宫内膜样成分的分级；（c）EC中良性或恶性鳞状分化的存在；（d）CC中实性与管状组织学类型；（e）肿瘤所在卵巢或盆腔其他部位的子宫内膜异位症；（f）肿瘤分期；（g）患者年龄；或（h）子宫内膜并存癌的存在。所有分期的EC、MC和CC的5年生存率分别为52%、22%和69%。I期EC和CC的5年生存率分别为82%和93%。这些差异均无统计学意义。所有三种肿瘤类型的疾病分期越高，以及EC和MC中子宫内膜样成分的分级越高，与生存率显著降低相关。与EC患者（17%）或MC患者（22%）相比，CC患者盆腔子宫内膜异位症的发生率显著增加（67%）（p<0.001）。EC中的良性或恶性鳞状分化、CC中的管状分化、患者年龄、子宫内膜异位症的存在或子宫内膜并存癌对生存率均无显著影响。
